Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model
Background: Cumulative anticholinergic exposure, also known as anticholinergic burden, is associated with a variety of adverse outcomes. However, studies show that anticholinergic effects tend to be underestimated by prescribers, and anticholinergics are the most frequently prescribed potentially in...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.577747/full |
id |
doaj-d28433595e7e4463a60a1edcc34b7af1 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Truc Sophia Dinh Ana Isabel González-González Ana Isabel González-González Andreas D. Meid Kym I. E. Snell Henrik Rudolf Maria-Sophie Brueckle Jeanet W. Blom Ulrich Thiem Ulrich Thiem Hans-Joachim Trampisch Petra J. M. Elders Norbert Donner-Banzhoff Ferdinand M. Gerlach Sebastian Harder Marjan van den Akker Paul P. Glasziou Walter E. Haefeli Christiane Muth Christiane Muth |
spellingShingle |
Truc Sophia Dinh Ana Isabel González-González Ana Isabel González-González Andreas D. Meid Kym I. E. Snell Henrik Rudolf Maria-Sophie Brueckle Jeanet W. Blom Ulrich Thiem Ulrich Thiem Hans-Joachim Trampisch Petra J. M. Elders Norbert Donner-Banzhoff Ferdinand M. Gerlach Sebastian Harder Marjan van den Akker Paul P. Glasziou Walter E. Haefeli Christiane Muth Christiane Muth Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model Frontiers in Pharmacology aged [MesH] anticholinergic burden accidental falls [MeSH] general practice prediction model prognosis research |
author_facet |
Truc Sophia Dinh Ana Isabel González-González Ana Isabel González-González Andreas D. Meid Kym I. E. Snell Henrik Rudolf Maria-Sophie Brueckle Jeanet W. Blom Ulrich Thiem Ulrich Thiem Hans-Joachim Trampisch Petra J. M. Elders Norbert Donner-Banzhoff Ferdinand M. Gerlach Sebastian Harder Marjan van den Akker Paul P. Glasziou Walter E. Haefeli Christiane Muth Christiane Muth |
author_sort |
Truc Sophia Dinh |
title |
Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model |
title_short |
Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model |
title_full |
Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model |
title_fullStr |
Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model |
title_full_unstemmed |
Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model |
title_sort |
are anticholinergic symptoms a risk factor for falls in older general practice patients with polypharmacy? study protocol for the development and validation of a prognostic model |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-01-01 |
description |
Background: Cumulative anticholinergic exposure, also known as anticholinergic burden, is associated with a variety of adverse outcomes. However, studies show that anticholinergic effects tend to be underestimated by prescribers, and anticholinergics are the most frequently prescribed potentially inappropriate medication in older patients. The grading systems and drugs included in existing scales to quantify anticholinergic burden differ considerably and do not adequately account for patients’ susceptibility to medications. Furthermore, their ability to link anticholinergic burden with adverse outcomes such as falls is unclear. This study aims to develop a prognostic model that predicts falls in older general practice patients, to assess the performance of several anticholinergic burden scales, and to quantify the added predictive value of anticholinergic symptoms in this context.Methods: Data from two cluster-randomized controlled trials investigating medication optimization in older general practice patients in Germany will be used. One trial (RIME, n = 1,197) will be used for the model development and the other trial (PRIMUM, n = 502) will be used to externally validate the model. A priori, candidate predictors will be selected based on a literature search, predictor availability, and clinical reasoning. Candidate predictors will include socio-demographics (e.g. age, sex), morbidity (e.g. single conditions), medication (e.g. polypharmacy, anticholinergic burden as defined by scales), and well-being (e.g. quality of life, physical function). A prognostic model including sociodemographic and lifestyle-related factors, as well as variables on morbidity, medication, health status, and well-being, will be developed, whereby the prognostic value of extending the model to include additional patient-reported symptoms will be also assessed. Logistic regression will be used for the binary outcome, which will be defined as “no falls” vs. “≥1 fall” within six months of baseline, as reported in patient interviews.Discussion: As the ability of different anticholinergic burden scales to predict falls in older patients is unclear, this study may provide insights into their relative importance as well as into the overall contribution of anticholinergic symptoms and other patient characteristics. The results may support general practitioners in their clinical decision-making and in prescribing fewer medications with anticholinergic properties. |
topic |
aged [MesH] anticholinergic burden accidental falls [MeSH] general practice prediction model prognosis research |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2020.577747/full |
work_keys_str_mv |
AT trucsophiadinh areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT anaisabelgonzalezgonzalez areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT anaisabelgonzalezgonzalez areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT andreasdmeid areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT kymiesnell areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT henrikrudolf areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT mariasophiebrueckle areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT jeanetwblom areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT ulrichthiem areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT ulrichthiem areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT hansjoachimtrampisch areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT petrajmelders areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT norbertdonnerbanzhoff areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT ferdinandmgerlach areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT sebastianharder areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT marjanvandenakker areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT paulpglasziou areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT walterehaefeli areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT christianemuth areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel AT christianemuth areanticholinergicsymptomsariskfactorforfallsinoldergeneralpracticepatientswithpolypharmacystudyprotocolforthedevelopmentandvalidationofaprognosticmodel |
_version_ |
1724336881564385280 |
spelling |
doaj-d28433595e7e4463a60a1edcc34b7af12021-01-15T13:50:42ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-01-011110.3389/fphar.2020.577747577747Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic ModelTruc Sophia Dinh0Ana Isabel González-González1Ana Isabel González-González2Andreas D. Meid3Kym I. E. Snell4Henrik Rudolf5Maria-Sophie Brueckle6Jeanet W. Blom7Ulrich Thiem8Ulrich Thiem9Hans-Joachim Trampisch10Petra J. M. Elders11Norbert Donner-Banzhoff12Ferdinand M. Gerlach13Sebastian Harder14Marjan van den Akker15Paul P. Glasziou16Walter E. Haefeli17Christiane Muth18Christiane Muth19Institute of General Practice, Goethe-University Frankfurt, Frankfurt, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, GermanyRed de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Madrid, SpainDepartment of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, GermanyCentre for Prognosis Research, School of Medicine, Keele University, Staffordshire, United KingdomDepartment of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, GermanyDepartment of Public Health and Primary Care, Leiden University Medical Center, Leiden, NetherlandsChair of Geriatrics and Gerontology, University Clinic Eppendorf, Hamburg, GermanyDepartment of Geriatrics, Immanuel Albertinen Diakonie, Albertinen-Haus, Hamburg, GermanyDepartment of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, GermanyAmsterdam UMC, General Practice and Elderly Care Medicine, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands0Department of General Practice/Family Medicine, Philipps University Marburg, Marburg, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, Germany1Institute of Clinical Pharmacology, Goethe-University Frankfurt am Main, Frankfurt am Main, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, Germany2Faculty of Health Sciences and Medicine, Bond University, Robina, QLD, AustraliaDepartment of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, GermanyInstitute of General Practice, Goethe-University Frankfurt, Frankfurt, Germany3Department of General Practice and Family Medicine, Medical Faculty OWL, University of Bielefeld, Bielefeld, GermanyBackground: Cumulative anticholinergic exposure, also known as anticholinergic burden, is associated with a variety of adverse outcomes. However, studies show that anticholinergic effects tend to be underestimated by prescribers, and anticholinergics are the most frequently prescribed potentially inappropriate medication in older patients. The grading systems and drugs included in existing scales to quantify anticholinergic burden differ considerably and do not adequately account for patients’ susceptibility to medications. Furthermore, their ability to link anticholinergic burden with adverse outcomes such as falls is unclear. This study aims to develop a prognostic model that predicts falls in older general practice patients, to assess the performance of several anticholinergic burden scales, and to quantify the added predictive value of anticholinergic symptoms in this context.Methods: Data from two cluster-randomized controlled trials investigating medication optimization in older general practice patients in Germany will be used. One trial (RIME, n = 1,197) will be used for the model development and the other trial (PRIMUM, n = 502) will be used to externally validate the model. A priori, candidate predictors will be selected based on a literature search, predictor availability, and clinical reasoning. Candidate predictors will include socio-demographics (e.g. age, sex), morbidity (e.g. single conditions), medication (e.g. polypharmacy, anticholinergic burden as defined by scales), and well-being (e.g. quality of life, physical function). A prognostic model including sociodemographic and lifestyle-related factors, as well as variables on morbidity, medication, health status, and well-being, will be developed, whereby the prognostic value of extending the model to include additional patient-reported symptoms will be also assessed. Logistic regression will be used for the binary outcome, which will be defined as “no falls” vs. “≥1 fall” within six months of baseline, as reported in patient interviews.Discussion: As the ability of different anticholinergic burden scales to predict falls in older patients is unclear, this study may provide insights into their relative importance as well as into the overall contribution of anticholinergic symptoms and other patient characteristics. The results may support general practitioners in their clinical decision-making and in prescribing fewer medications with anticholinergic properties.https://www.frontiersin.org/articles/10.3389/fphar.2020.577747/fullaged [MesH]anticholinergic burdenaccidental falls [MeSH]general practiceprediction modelprognosis research |